Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review found that valproic acid treatment significantly increases the risk of alopecia compared to other drugs, regardless of dose or treatment duration.

This case report describes a 47-year-old woman who experienced reversible curling of her hair during treatment with valproic acid, suggesting potential side effects on hair texture.

This study found that valproic acid and crocin, alone or together, significantly increased the expression levels of neurotrophic factors in rat-derived epidermal neural crest stem cells, suggesting therapeutic potential for neurological disorders.

In this study, behavioral disturbances were commonly observed with levetiracetam, while somnolence was frequently reported with oxcarbazepine among patients with refractory epilepsy.

This study concluded that male mice are more susceptible to valproic acid-induced autism spectrum disorder than female mice, with noticeable differences in brain histoarchitecture and receptor protein levels.

This study demonstrated that dermal papilla cells were more efficiently reprogrammed into induced pluripotent stem cells than dermal fibroblasts, suggesting their potential as a source for iPS cells.

This article presents five cases of valproate-induced hyperammonemic encephalopathy in psychiatric patients treated at the authors' clinic and discusses existing literature on this side effect.

This study found that valproate sustained-release monotherapy provided effective short-term seizure control and was well tolerated in newly-diagnosed epileptic patients with partial seizures in the Gulf Cooperation Council countries.

This study found that topical valproate has minimal potential to cause skin irritation, suggesting it can be applied safely to human skin.

This correspondence article discusses a case of androgenetic alopecia treated with valproic acid but does not present new clinical findings.

This case report describes a patient experiencing nail nonadherence due to sterile matrix scarring associated with valproic acid use, and suggests nail bed excision with sterile matrix grafting as a potential surgical solution.

Platelet-rich plasma doesn't prevent hair loss from chemotherapy, and mononuclear cells only help against hair loss from one specific chemotherapy drug.

In this study, researchers developed a composite paste system using minoxidil-loaded nanoparticles and valproic acid, enhanced by roller-microneedles, which significantly stimulated hair regeneration and perifollicular vascularization in an androgenetic alopecia mouse model, reducing side effects compared to traditional treatments.

This study analyzed hair styling mousses on the Slovenian market, finding that their formulations primarily rely on polymers, with no banned ingredients according to European cosmetics regulations.

In this study, Mononuclear Cells provided site-specific protection against chemotherapy-induced alopecia in rats treated with Ara-C, but not with CTX or VP-16, while PRP showed no protective effect.

This study found that using a palmitoylated peptide, Pal-MPAPO, delivered through hydrogel microneedles effectively promoted hair regrowth in mice with efficacy comparable to minoxidil, while requiring less frequent application.

This scoping review aims to map current knowledge about treatment strategies for alopecia caused by VPA (valproic acid) across various patient groups, identifying reported management strategies, supporting evidence, observed outcomes, and areas needing further research, but results are not provided.

This study found that preconditioning human hair follicle-derived stem cells with valproic acid enhanced their survival and migration in ischemic-like conditions by activating autophagy and inhibiting the AKT/mTOR pathway, suggesting this approach could improve stem cell therapies for ischemic stroke.

This study found that individuals taking valproate had a higher incidence of hair loss and reported an association between valproate levels, reduced biotinidase activity, and hair loss, compared to a control group.

This study found that vinegar-processed black soybean and its extract accelerated hair growth and prevented alopecia in mice, with potential mechanisms involving modulation of the Wnt/β-catenin signaling pathway, suggesting they may be promising functional foods for hair regeneration.

This observational study found that while 96.6% of patients using valproic acid showed the expected clinical response, over half experienced adverse reactions like weight gain, hair loss, and hepatotoxicity, highlighting the need for personalized treatment approaches to minimize these side effects.

This study found that a novel choline-based valproic acid ionic liquid significantly enhances transdermal penetration and promotes hair regrowth without causing irritation or toxicity, offering a promising treatment option for alopecia.

In this study conducted on mouse fetuses, valproic acid was found to reduce Sonic Hedgehog expression in the skin and hair follicles, but the inclusion of vitamin E helped mitigate this effect, supporting its potential role in managing valproic acid-induced changes.

This study found that dual ASM therapies involving valproic acid were associated with poorer tolerability and specific adverse events, with cognitive side effects occurring prominently across all examined combinations.

This study found that in patients with genetic generalized epilepsies, certain gene variants were linked to differences in valproic acid treatment outcomes, including a higher likelihood of treatment failure, varying serum drug concentrations, and specific side effects like weight gain and hair loss.

In this study, preconditioning hair follicle-derived stem cells with valproic acid and/or rapamycin was shown to protect against damage caused by oxygen glucose and serum deprivation, potentially enhancing stem cell therapy efficacy for ischemic stroke by improving cell adaptation to oxidative stress.

In this study, valproic acid, levetiracetam, and phenytoin were the main anti-seizure medications associated with adverse drug reactions in pediatric epilepsy patients, with younger children and those on polytherapy at higher risk.

In this commentary, the authors highlighted that valproic acid, unlike lamotrigine, is notably associated with alopecia in various studies, with an incidence rate up to 12% and mechanisms involving telogen effluvium and hyperandrogenism contributing to hair loss in patients.

The research investigated the effects of antiandrogens on neurodevelopmental milestones in rats exposed to valproic acid during pregnancy, finding that while valproic acid delayed sensorimotor reflexes, it didn't impact physical development milestones, and antiandrogens partially mitigated these delays.

This review compiles recent findings on the pharmacokinetics, pharmacodynamics, and pharmacogenomics of Valproate, highlighting potential new uses, benefits, and risks, but reports no new clinical results.